Vertical inhibition, which involves targeting both upstream and downstream components of the same pathway, has shown promise in therapeutic interventions, analogous to the successful BRAF/MEK inhibition strategy in BRAF mutant cancers (75–77). The gene discussed is MAP2K7; the disease is cancer.